Incannex Healthcare Limited closed at $2.49 on Nov 4, down 0.60%, 82.7% below its 52-week closing high. Volume of 37.0K shares was 0.53× its 20-day average (below normal).
Split-adjusted performance: -21.5% over one month, -49.3% over six months, -76.6% over one year.
Short interest was 411.6K shares at the Oct 15 settlement, down 9.8% from the prior report (3.3% of float, 6.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IXHLIncannex Healthcare Limited | $2.49 | −0.60% | −49.3% | — | — | — | $31.2M | |
| PMNProMIS Neurosciences Inc. Common Shares (ON) | $3.52 | +3.23% | −68.0% | — | — | — | $31.6M | Compare |
| RMTIRockwell Medical, Inc. (DE) | $8.05 | −0.49% | −0.6% | +10.6% | −7.5% | — | $32.4M | Compare |
| LITSLite Strategy | $1.08 | +3.85% | −9.2% | — | — | — | $32.8M | Compare |
| ACETAdicet Bio | $3.10 | −2.21% | −63.7% | — | — | — | $29.0M | Compare |
| BYSIBeyondSpring | $0.6790 | +9.34% | −56.2% | — | — | — | $27.9M | Compare |
| BCTXBriacell Therapeutics | $3.19 | +5.98% | −23.1% | — | — | — | $27.9M | Compare |
| IBOImpact BioMedical | $4.10 | +1.99% | −48.8% | −57.1% | −23300.0% | 44.4 | $35.0M | Compare |
| NNVCNanoViricides | $1.38 | −3.50% | −5.5% | — | — | — | $35.2M | Compare |
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
